Teva Pharmaceutical Cash Flow - Quarterly (NYSE:TEVA)

Add to My Stocks
$24.05 $0.17 (0.7%) TEVA stock closing price Jun 19, 2018 (Closing)

The cash flow statement is one of the reports a publicly traded company like Teva Pharmaceutical needs to disclose. The profit-loss statement shows Teva Pharmaceutical profits, the balance sheet shows Teva Pharmaceutical debt, and the cash flow statement reflects the liquidity and solvency of a firm. This statement reflects the company's ability to generate cash flows. This statement can tell if a company is running out of money while still being profitable and is useful in Teva Pharmaceutical stock analysis. Teva Pharmaceutical had a positive net income cash flow of $1.13B till this quarter of 2018 Q1. This report is very useful in measuring the short term viability of a company. The cash from operating activities for Teva Pharmaceutical is $ 2018 Q1, which saw a decrease from previous quarter.

View and download details of Teva Pharmaceutical cash flows for latest & last 40 quarters
show more
Quarterly
Annual
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q12015 Q4
Net Income Cash Flow
1.13B-16.45B-4.72B-5.33B641M311M1.29B875M633M1.6B
Depreciation Depletion Amortization Cash-Flow507M2.11B1.58B1.06B480M1.52B1.19B615M305M1.31B
Net Increase (Decrease) in Assets Liabilities-592M-363M-755M-711M-463M1.22B1.1B53M189M967M
Cash From (used in) Discontinued Operations----------
Other Adjustments Net447M18.21B6.22B6.19B-188M2.17B223M796M249M1.67B
Net Cash from (used by) Operating Activities
1.5B3.51B2.33B1.21B470M5.23B3.8B2.34B1.38B5.54B
Increase (Decrease) in Prop Plant And Equipment661M2.6B1B1.09B1.21B1.1B1.23B-308M-170M-248M
Acquisition Disposition of Subsidiaires-43M43M---36.15B-35.87B-2.31B-2.24B-3.31B
Increase (Decrease) in Investments-56M-200M-194M-14M-6M-481M-316M-37M-29M-2B
Other Cash Inflow (Outflow) from Investment Activities434M-282M-277M-286M-22M-212M15M15M18M-5M
Net Cash from (used by) Investment Activities
1.04B2.16B572M790M1.18B-35.74B-34.94B-2.64B-2.42B-5.57B
Issuance (Purchase) of Equity Shares-----364M363M349M342M3.24B
Issuance (Repayment) of Debt Securities-1.8B-2.79B-498M-62M-24.58B25.53B284M285M2.87B
Increase (Decrease) in Bank & Other Borrowings-261M-1.68B-1.63B-1.48B-1.35B2B1.32B758M38M29M
Payment of Dividends & Other Cash Distributions-22M-1.16B-1.01B-821M-411M-1.56B-1.15B-743M-367M-1.16B
Other Cash from (used by) Financing Activities-5M-112M-107M-59M-7M-169M-143M-102M-31M-178M
Net Cash from (used by) Financing Activities
-2.09B-5.75B-3.24B-2.42B-1.77B25.22B25.92B546M267M4.81B
Effect of Exchange Rate Changes on Cash11M54M36M29M28M-660M-164M-205M-208M-62M
Net Change in Cash & Cash Equivalents
455M-25M-308M-389M-88M-5.96B-5.39B38M-982M4.72B
Cash & Equivalents at Beginning of Year988M6.95B2.23B1.04B2.88B1.1B1.25B2B1.85B1.49B
Cash & Equivalents at Year End1.42B963M680M599M900M988M1.56B6.98B5.96B6.95B
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Teva Pharmaceutical stock price history provides insight into historical stock price fluctuations, and Teva Pharmaceutical stock comparison chart enables peer comparison. Some of the key terms used in the statement of cash flows are:

  • Teva Pharmaceutical saw a positive change in Net Change in Cash and Cash Equivalents of $455M till 2018 Q1. Apart from the Teva Pharmaceutical stock price, this is one of the things an investor looks for, as it shows the net change in cash on hand for a company, compared to previous period.
  • Teva Pharmaceutical increased its cash from operating activities to $1.5B till 2018 Q1. Operating activities include production of goods or creating a product or providing a service, and collecting payment for the same from customers. The cash generated from these activities is refered to as cash flow from operating activities.
  • Cash Flow from investment activities: This includes buying/selling of land and equipment, acquisitions and mergers, sell-off, investment in other companies like buying bonds, stocks etc., and was $1.04B for TEVA till last quarter 2018 Q1 report.
  • Cash Flow from financing activities: The cash inflow/outflow from financing activities was $-2.09B for Teva Pharmaceutical. The money accounted for under this head comes from external sources which includes lenders, investors and shareholders. Positive cash flow is generated when the company gets cash because of issuance of stocks or bonds. Similarly negative cash flow is generated when shares are repurchased, dividend payments are made, and loans or interest on loans are paid back.

Key Financial Ratios For Teva Pharmaceutical Cash Flow

FCF margin
0.43

Quarterly Cash Flow Statements For Teva Pharmaceutical Industries Ltd (ADR) Peers

Allergan cash flow, Astrazeneca cash flow, Eagle Pharma cash flow, Fortress Biotech cash flow, Mylan cash flow